Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 4/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.35 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | MAOA | P21397 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2843050 | 0.84 | NISCH (0.46) | NISCHGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL7723209 | 0.81 | GABRA1 (0.64) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2843801 | 0.77 | NISCH (0.49) | NISCHGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL2847576 | 0.77 | GABRA1 (0.45) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL7722413 | 0.71 | GABRA1 (0.70) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1199144 | 0.69 | NISCH (0.42) | NISCHGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL16063032 | 0.69 | GABRA1 (0.67) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL9667241 | 0.65 | NISCH (0.60) | NISCHGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL29505417 | 0.64 | APP (0.47) | — | |
| SCHEMBL25171710 | 0.64 | TDO2 (0.40) | MAOBMAOATSHRALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE47475-E1 | Selective agents for pain suppression | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20100317619-A1 | Selective Agents for Pain Suppression | COOK JAMES | 2010-12-16 | — | — | US | disclosed |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | WISYS TECHNOLOGY FOUNDATION (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-05-27 | — | — | US | disclosed |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | COOK JAMES M | 2010-01-07 | — | — | US | disclosed |
| US-7618958-B2 | Convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnosis; Ethyl 8-bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2009-11-17 | — | — | US | disclosed |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2008-05-08 | — | — | US | disclosed |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-7235656-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-06-26 | — | — | US | disclosed |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-7119196-B2 | Anxiolytic agents with reduced sedative and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | WISYS TECHNOLOGY FOUNDATION, INC. (US) | 2006-01-05 | — | — | US | disclosed |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049580-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | NISCH 1200/4885GABRA1 3/4885GABRG2 14/4885 |
| US-20100317619-A1 | Selective Agents for Pain Suppression | CNR2, CNR1, OPRL1 | NISCH 2008/4885GABRA1 12/4885GABRG2 25/4885 |
| US-20060003995-A1 | Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects | GABRE, GABRA6, GABRA5 | NISCH 2975/4885GABRA1 4/4885GABRG2 21/4885 |
| US-20100130481-A1 | ANTICONVULSANT AND ANXIOLYTIC METHODS OF USING RECEPTOR SUBTYPE SELECTIVE AGENTS | GABRA3, GABRA2, GABRA1 | NISCH 2331/4885GABRA1 3/4885GABRG2 15/4885 |
| US-20040082573-A1 | Anxiolytic agents with reduced sedative and ataxic effects | GABRA3, GABRA2, GABRA1 | NISCH 1200/4885GABRA1 3/4885GABRG2 14/4885 |
| US-20070299058-A1 | Anxiolytic Agents With Reduced Sedative And Ataxic Effects | GABRA3, GABRA2, GABRA1 | NISCH 1200/4885GABRA1 3/4885GABRG2 14/4885 |
| US-20080108605-A1 | ANXIOLYTIC AGENTS WITH REDUCED SEDATIVE AND ATAXIC EFFECTS | GABRA3, GABRA2, GABRA1 | NISCH 1200/4885GABRA1 3/4885GABRG2 14/4885 |
| US-20070054881-A1 | Orally active benzodiazepine derivatives and their salts; anticonvulsants with reduced hypnotic and muscle relaxant side effects; eating and psychological disorders | GABRA3, GABRA6, GABRA4 | NISCH 1421/4885GABRA1 5/4885GABRG2 14/4885 |
| US-20100004226-A1 | STEREOSPECIFIC ANXIOLYTIC AND ANTICONVULSANT AGENTS WITH REDUCED MUSCLE-RELAXANT, SEDATIVE-HYPNOTIC AND ATAXIC EFFECTS | CHRNA6, GABRA6, CHRNA5 | NISCH 3104/4885GABRA1 7/4885GABRG2 24/4885 |
| US-20100261711-A1 | SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES | GABRA5, GABRA6, GABRA2 | NISCH 1654/4885GABRA1 4/4885GABRG2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.